No Data
Mira Pharmaceuticals Announced The Selection Of The Centre For Human Drug Research In Leiden, The Netherlands, As The Site For Its Phase I/IIa Clinical Trial Of Ketamir-2, A Novel Oral Ketamine Analog
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
US Manufacturing Index Rises To 43, Highest Since 2020
MIRA Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
No Data
No Data